Abstract
Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoma tissue (MALT) among intraoral malignant lymphomas is very rare. Moreover, no case of oral MALT lymphoma treated with monoclonal antibody therapy has been reported. We describe a case of MALT lymphoma arising in an 87-year-old Japanese woman under the buccal mucosa that was successfully treated with rituximab, a chimeric monoclonal antibody against the B cell-specific antigen CD20. Currently, 5 months after completing treatment, the patient is alive and has partial regression of the tumor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
